Responses
Clinical/translational cancer immunotherapy
Original research
Safety and efficacy of restarting immune checkpoint inhibitors after clinically significant immune-related adverse events in metastatic renal cell carcinoma
Compose a Response to This Article
Other responses
No responses have been published for this article.